Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MYJ1633-CTS
- Development stage
- Preclinical
- Lead developer
- IMMUNISBIO
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
MYJ1633-CTS is an investigational natural killer (NK) cell therapy being developed by ImmunisBio. Categorized as a "Cancer-Target NK" (CT-NK) therapy, it utilizes activated and expanded NK cells designed to specifically target and eliminate malignant cells. The program is currently focused on the treatment of triple-negative breast cancer (TNBC), a subtype of breast cancer known for its aggressive nature and lack of targeted treatment options. MYJ1633-CTS is currently in the IND-enabling stage of development, representing an advancement of the company's core NK cell platform (MYJ1633) with enhanced targeting capabilities.
- Other names
- Cancer-Target NK
Beyond the preview
Go deeper on MYJ1633-CTS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MYJ1633-CTS.